Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBM-01 for Ataxia Telangiectasia
NCT04887311Phase 2Unknown
- Sponsor
- Matrix Biomed, Inc.
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MBI-201.0 in ataxia-telangiectasia (AT), sponsored by Matrix Biomed, Inc. Primary endpoint: International Cooperative Ataxia Rating Scale at Month 9. Status: unknown.
02
Drugs
MBI-201.0
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT04887311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887311.